Skip to main content

Allergan, Molecular Partners eye drug meets main goal in two studies

Allergan Plc and Molecular Partners AG said on Thursday their treatment for age-related macular degeneration met the main goal in two late-stage studies.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.